Why the study?
Does CRT-D reduce the risk of heart failure or death in diabetic patients with ischemic or nonischemic cardiomyopathy compared to defibrillator-only?
Does CRT-D reduce the risk of heart failure or death in diabetic patients with ischemic or nonischemic cardiomyopathy compared to defibrillator-only?
CRT-D provides substantial clinical and echocardiographic benefits in diabetic patients with cardiomyopathy, with a particularly pronounced benefit in those with nonischemic etiology.
No takes yet. Share an insight, caveat, or question.
May support CRT-D consideration in diabetic cardiomyopathy; hypothesis-generating for etiology-specific effects pending randomized confirmation.
George et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: